Background Dementia with Lewy bodies (DLB) is underrecognised in clinical settings. Aims To investigate whether performing a 123I-ioflupane injection (123I-FP-CIT also called DaTSCANTM) single photon emission computed tomography (SPECT) scan in patients with possible DLB would lead to a more certain diagnosis (probable DLB or non-DLB dementia). Method We randomised 187 patients with possible DLB 2:1 to have a scan or not (control group). The outcome measure was a change in diagnosis to probable DLB or non-DLB. Results There were 56 controls and 114 scanned patients, of whom 43% had an abnormal scan. More patients in the imaging group had a change in diagnosis compared with controls at 8 and 24 weeks (61% (n = 70) v. 4% (n = 2) and 71% (n = 77) v. 16% (n = 9); both P50.0001). Clinicians were more likely to change the diagnosis if the scan was abnormal (82%) than if it was normal (46%). Conclusions Imaging significantly contributed to a more certain diagnosis, proving to be a useful adjunct in the work-up of patients with possible DLB. Declaration of interest Z.W. has received funding for travel, consultancy and speaker fees and research support from GE Healthcare (GEHC), consultancy fees from Bayer Healthcare and Novartis and research support from Lundbeck. N.T. has received speaker fees from Eli Lilly and Pfizer and consultancy fees from GEHC. E.M. is a full time employee of GEHC. F.I. has received speaker fees as a consultant to Pfizer and funding for research work conducted with Abbott Laboratories Ltd, Eli Lilly, GEHC, Genentech, Medivation Inc, Noscira, Pfizer and Roche. A.T. has received research support for an investigator-led study from GEHC.
Clinical usefulness of dopamine transporter SPECT imaging with 123I-FP-CIT in patients with possible dementia with Lewy bodies: randomised study.
CERAVOLO, ROBERTO
2015-01-01
Abstract
Background Dementia with Lewy bodies (DLB) is underrecognised in clinical settings. Aims To investigate whether performing a 123I-ioflupane injection (123I-FP-CIT also called DaTSCANTM) single photon emission computed tomography (SPECT) scan in patients with possible DLB would lead to a more certain diagnosis (probable DLB or non-DLB dementia). Method We randomised 187 patients with possible DLB 2:1 to have a scan or not (control group). The outcome measure was a change in diagnosis to probable DLB or non-DLB. Results There were 56 controls and 114 scanned patients, of whom 43% had an abnormal scan. More patients in the imaging group had a change in diagnosis compared with controls at 8 and 24 weeks (61% (n = 70) v. 4% (n = 2) and 71% (n = 77) v. 16% (n = 9); both P50.0001). Clinicians were more likely to change the diagnosis if the scan was abnormal (82%) than if it was normal (46%). Conclusions Imaging significantly contributed to a more certain diagnosis, proving to be a useful adjunct in the work-up of patients with possible DLB. Declaration of interest Z.W. has received funding for travel, consultancy and speaker fees and research support from GE Healthcare (GEHC), consultancy fees from Bayer Healthcare and Novartis and research support from Lundbeck. N.T. has received speaker fees from Eli Lilly and Pfizer and consultancy fees from GEHC. E.M. is a full time employee of GEHC. F.I. has received speaker fees as a consultant to Pfizer and funding for research work conducted with Abbott Laboratories Ltd, Eli Lilly, GEHC, Genentech, Medivation Inc, Noscira, Pfizer and Roche. A.T. has received research support for an investigator-led study from GEHC.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
